Aerus ActivePure Technology Announces SARS-CoV-2 Test
Results
Aerus ActivePure Air and Surface Purifier Provides 99.98% COVID-19 Surface
Reduction Rate in Controlled, Independent Laboratory Studies
DALLAS (September 30, 2020) , Aerus, the global leader in air and surface purification
solutions, announced today that testing data conducted by independent FDA-compliant
laboratory, MRIGlobal, established a 99.98% surface kill rate of live SARS-CoV-2 virus in
just 7 hours with the Aerus Hydroxyl Blaster air and surface purifier.
Data collected in the study showed a 93% surface kill in 3 hours and 98% surface kill in 6
hours of live SARS-CoV-2, even when covered by a protective biofilm, with the Aerus
Hydroxyl Blaster and its patented ActivePure Technology.
In addition, Aerus is running independent laboratory tests to
demonstrate the efficacy of ActivePure Technology on
airborne SARS-CoV-2 virus. These results will be submitted
to the FDA for review and clearance. Aerus Technology has a
99.9999% kill rate of airborne RNA viruses in just 60
minutes and 99.999% in 30 minutes, as proven with the FDA
510(k) cleared Aerus Medical Guardian with ActivePure, and
performs materially faster on airborne pathogens while it
simultaneously destroys surface pathogens. The patented,
photocatalyst ActivePure Technology in the Aerus Hydroxyl
Blaster is the same ActivePure Technology used in the Aerus
FDA Class II Medical Device, the Aerus Medical Guardian.
Aerus is confident its upcoming SARS-CoV-2 RNA virus
airborne tests will demonstrate strong performance both in
speed and the reduction level of the SARS-CoV-2 virus in the
air, based on the airborne test results with non-lipid
surrogate, MS2 Bacteriophage RNA virus. The SARS-CoV-2
RNA virus is a lipid virus, which the FDA has acknowledged is
easier to destroy than non-lipid viruses. Aerus is working
expeditiously to confirm the airborne disinfection rate on the
SARS-CoV-2 virus. When available, this data will be
submitted to the FDA for clearance.
Aerus is awaiting final approval from the U.S. Food and Drug Administration (FDA) for
Emergency Use Authorization (EUA) for the Aerus Hydroxyl Blaster with ActivePure
Technology for use in reducing SARS-CoV-2 surface pathogens. The results have also been
submitted by Aerus to the FDA-equivalent Canadian and European Union regulators,
requesting that they clear Aerus ActivePure devices to combat the SARS-CoV-2
coronavirus. Aerus expects to receive clearances in all jurisdictions in the near future
